USA - engelska - NLM (National Library of Medicine)

legacy pharmaceutical packaging, llc - glipizide (unii: x7wdt95n5c) (glipizide - unii:x7wdt95n5c) - glipizide 5 mg - glipizide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glipizide is contraindicated in patients with: 1. known hypersensitivity to the drug.   2.  type 1 diabetes mellitus, diabetic ketoacidosis, with or without coma. this condition should be treated with insulin.

USA - engelska - NLM (National Library of Medicine)

legacy pharmaceutical packaging, llc - metoprolol succinate (unii: th25pd4ccb) (metoprolol - unii:geb06nhm23) - metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic

USA - engelska - NLM (National Library of Medicine)

legacy pharmaceutical packaging, llc - atorvastatin calcium trihydrate (unii: 48a5m73z4q) (atorvastatin - unii:a0jwa85v8f) - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in patients with chd or multiple risk factors for chd, atorvastatin calcium tablets can be started simultaneously with diet. in adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low hdl-c, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: - reduce the risk of myocardial infarction - reduce the risk of stroke - reduce the risk for revascularization procedures and angina in adult patients with type 2 diabetes, and without clinically evident coronary heart di

USA - engelska - NLM (National Library of Medicine)

legacy pharmaceutical packaging, llc - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (du). • active gastric ulcer (gu). • symptomatic nonerosive gastroesophageal reflux disease (gerd). • erosive esophagitis due to gerd, diagnosed by biopsy. famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. famotidine tablets are contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (h 2 ) receptor antagonists. risk summary available data with h 2 -receptor antagonists, including famotidine, in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. in animal reproduction studies, no adverse development effects were observed with oral administration of famotidine at doses up to approximately 243 and 122 times, respectively, the recommended human dose of 80 mg per day for the treatment of erosive esophagitis (see data) . the estimated background risk for major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. data animal data reproductive studies have been performed in rats and rabbits at oral doses of up to 2,000 and 500 mg/kg/day, respectively, and in both species at intravenous doses of up to 200 mg/kg/day, and have revealed no significant evidence of impaired fertility or harm to the fetus due to famotidine. while no direct fetotoxic effects have been observed, sporadic abortions occurring only in mothers displaying marked decreased food intake were seen in some rabbits at oral doses of 200 mg/kg/day (about 49 times the recommended human dose of 80 mg per day, based on body surface area) or higher. there are, however, no adequate or well-controlled studies in pregnant women. because animal reproductive studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. risk summary there are limited data available on the presence of famotidine in human breast milk. there were no effects on the breastfed infant. there are no data on famotidine effects on milk production. famotidine is present in the milk of lactating rats (see data) . the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for famotidine and any potential adverse effects on the breastfed child from famotidine or from the underlying maternal condition. data animal data transient growth depression was observed in young rats suckling from mothers treated with maternotoxic doses of famotidine at least 600 times the usual human dose. the safety and effectiveness of famotidine have been established in pediatric patients for the treatment of peptic ulcer disease (i.e., duodenal ulcer, gastric ulcer) and gerd (i.e., symptomatic nonerosive gerd, erosive esophagitis as diagnosed by endoscopy). the use of famotidine and the recommended dosage of famotidine in these pediatric patients is supported by evidence from adequate and well-controlled studies of famotidine in adults and published pharmacokinetic and pharmacodynamic data in pediatric patients [see dosage and administration ( 2.1), clinical pharmacology ( 12.2, 12.3)] . in pediatric patients, the safety and effectiveness for the treatment of pathological hypersecretory conditions and reduction of risk of duodenal ulcer recurrence have not been established. famotidine 20 and 40 mg tablets are not recommended for use in pediatric patients weighing less than 40 kg because these tablet strengths exceed the recommended dose for these patients [see dosage and administration ( 2.1)] . for pediatric patients weighing less than 40 kg, consider another famotidine formulation (e.g., oral suspension, lower dose tablet). of the 1,442 famotidine-treated patients in clinical studies, approximately 10% were 65 and older. in these studies, no overall differences in safety or effectiveness were observed between elderly and younger patients. in postmarketing experience, cns adverse reactions have been reported in elderly patients with and without renal impairment receiving famotidine [see warnings and precautions ( 5.1)]. famotidine is known to be substantially excreted by the kidney, and the risk of adverse reactions to famotidine may be greater in elderly patients, particularly those with impaired renal function [see use in specific populations ( 8.6)]. in general, use the lowest effective dose of famotidine for an elderly patient and monitor renal function [see dosage and administration ( 2.2)]. cns adverse reactions and prolonged qt intervals have been reported in patients with moderate and severe renal impairment [see warnings and precautions ( 5.1)]. the clearance of famotidine is reduced in adults with moderate and severe renal impairment compared to adults with normal renal function [see clinical pharmacology ( 12.3)] . no dosage adjustment is needed in patients with mild renal impairment (creatinine clearance greater than or equal to 60 ml/minute). dosage reduction is recommended in adult and pediatric patients greater than or equal to 40 kg with moderate or severe renal impairment (creatinine clearance less than 60 ml/minute) [see dosage and administration ( 2.2)] .

USA - engelska - NLM (National Library of Medicine)

legacy pharmaceutical packaging - doxycycline hyclate (unii: 19xts3t51u) (doxycycline anhydrous - unii:334895s862) - doxycycline hyclate 100 mg - to reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. doxycycline is indicated for the treatment of the following infections: • rocky mountain spotted fever, typhus fever and the typhus group, q fever, rickettsialpox, and tick fevers caused by rickettsiae. • respiratory tract infections caused by mycoplasma pneumoniae . • lymphogranuloma venereum caused by chlamydia trachomatis . • psittacosis (ornithosis) caused by chlamydia psittaci . • trachoma caused by chlamydia trachomatis , although the infectious agent is not always elimi

USA - engelska - NLM (National Library of Medicine)

legacy pharmaceutical packaging - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril 12.5 mg - hypertension : captopril tablets usp are indicated for the treatment of hypertension. in using captopril, consideration should be given to the risk of neutropenia/ agranulocytosis (see warnings ). captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. in patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. heart failure : captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. the beneficial effect of captopril in heart failure does not require the presen

USA - engelska - NLM (National Library of Medicine)

legacy pharmaceutical packaging - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x), phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - atropine sulfate 0.0194 mg - glaucoma, obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus, intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis especially if complicated by toxic magacolon; myasthenia gravis; hiatal hernia associated with reflux esophagitis. belladonna alkaloids with phenobarbital tablets are contraindicated in patients with known hypersensitivity to any of the ingredients. phenobarbital is contraindicated in acute intermittent porphyria and in those patients in whom phenobarbital produces restlessness and/or excitement.

USA - engelska - NLM (National Library of Medicine)

legacy pharmaceutical packaging - lisinopril (unii: e7199s1ywr) (lisinopril - unii:e7199s1ywr) - lisinopril 20 mg - hypertension: lisinopril tablets are indicated for the treatment of hypertension. it may be used alone as initial therapy or concomitantly with other classes of antihypertensive agents. heart failure: lisinopril tablets are indicated as adjunctive therapy in the management of heart failure in patients who are not responding adequately to diuretics and digitalis. acute myocardial infarction: lisinopril tablets are indicated for the treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction, to improve survival. patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin and beta blockers. in using lisinopril tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk. (see warn

USA - engelska - NLM (National Library of Medicine)

legacy pharmaceutical packaging - cyclobenzaprine hydrochloride (unii: 0ve05jys2p) (cyclobenzaprine - unii:69o5wqq5ti) - cyclobenzaprine hydrochloride 5 mg

USA - engelska - NLM (National Library of Medicine)

legacy pharmaceutical packaging - atorvastatin calcium (unii: 48a5m73z4q) (atorvastatin - unii:a0jwa85v8f) - atorvastatin 10 mg